(Q35183548)

7 August 2017

1 reference

title

Identifying the child in need of asthma therapy (English)

1 reference

7 August 2017

1 reference

1

Stanley J Szefler

1 reference

7 August 2017

publication date

1 June 2003

1 reference

Pediatric Clinics of North America

7 August 2017

published in

1 reference

7 August 2017

volume

50

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

577-591

1 reference

Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Childhood asthma: new insights into management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Inhaled corticosteroids: impact on asthma morbidity and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Long-term effects of budesonide or nedocromil in children with asthma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Asthma and wheezing in the first six years of life. The Group Health Medical Associates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

The Melbourne Asthma Study: 1964-1999.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Effect of long-term treatment with inhaled budesonide on adult height in children with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Endotoxin exposure in allergy and asthma: reconciling a paradox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

A clinical index to define risk of asthma in young children with recurrent wheezing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Significant variability in response to inhaled corticosteroids for persistent asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Children with difficult asthma: a practical approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Increased interleukin-4 and decreased interferon-gamma in exhaled breath condensate of children with asthma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

7 January 2021

DNA therapy for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Contributing factors to the pathobiology. The genetics of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Pharmacogenetics of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Pharmacogenetics of Asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

The R576 IL-4 receptor alpha allele correlates with asthma severity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Maturation of immune responses at the beginning of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Trends in childhood asthma: prevalence, health care utilization, and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Relationship of adherence to pediatric asthma morbidity among inner-city children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

Improving childhood asthma outcomes in the United States: a blueprint for policy action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2803%2900041-5

10.1016/S0031-3955(03)00041-5

7 January 2021

Identifiers

DOI

1 reference

7 August 2017

1 reference